0.000USD0.000åå ŽååŒÂ 07/28, 09:30 (ET)
20.30BæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
17.330å§å€
17.750é«å€
9.76Måºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
6.62äºæ³PER
0.480çŽè¿12ã¶æé
åœ
0.85%売買å転ç
17.240忥çµå€
17.280å®å€
125.44M売買代é
æå€±é¡æ ªäŸ¡åçç
1.38PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
2.72%çŽè¿12ã¶æé
åœå©åã
-0.79%ç·è³ç£å©çç
17.53052é±é«å€
1.05åºæ¥é«æ¯ç%
-634.20MçŽå©ç
1.15Bæ ªåŒæ°
-0.29861æ ªåœããå©çïŒEPSïŒ
0.89ããŒã¿å€
-1.96%èªå·±è³æ¬å©çç
8.40052é±å®å€
2.73%æ¯ãå¹
39.18%ç²å©çç
20.30BæäŸ¡ç·é¡
3.02ãªã¹ã¯ãªã¿ãŒã³
1.84%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-27 äž»èŠã€ã³ãµã€ã
Viatris Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçå®å®ã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸããå»è¬åæ¥çã§ã®é äœã¯155äž30äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããéå»1ãæéã«è€æ°ã®ã¢ããªã¹ããè²·ããšè©äŸ¡ããæé«ç®æšæ ªäŸ¡ã¯17.59ãšãããŠããŸããäžæçã«ã¯ãæ ªäŸ¡ã¯äžæãã¬ã³ããšäºæ³ãããŸããéå»1ãæã®æ ªåŒåžå Žã®ããã©ãŒãã³ã¹ã¯è¯å¥œã§ããã¡ã³ãã¡ã³ã¿ã«ãºãåªããŠããŸãããããã¯ãã«ã«ã¯çŸåšã®ãã¬ã³ããè£ä»ãããã®ã§ã¯ãããŸãããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Viatris Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Viatris Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Viatris Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
åçäºæž¬î
匷åè²·ã
è²·ã
äžç«
売ã
匷å売ã
ææšî
ææš
売ã(1)
äžç«(2)
è²·ã(3)
ç§»åå¹³å
売ã(0)
äžç«(0)
è²·ã(6)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Viatris Incã®äŒæ¥æ
å ±î
Viatris Inc. is a global healthcare company. The Company's segments include Developed Markets, Greater China, JANZ, and Emerging Markets. The Developed Markets segment comprises its operations primarily in North America and Europe. The Greater China segment includes its operations in China, Taiwan and Hong Kong. The JANZ segment reflects its operations in Japan, Australia, and New Zealand. The Emerging Markets segment encompasses its presence in more than 125 countries with developing markets and emerging economies, including in Asia, Africa, Eastern Europe, Latin America, and the Middle East, as well as the Companyâs Antiretroviral medicines (ARV) franchise. Its pipeline and research and development capabilities include expertise in formulation, device development, toxicology, analytical, clinical, bioanalytical, medical affairs, product safety and risk management across a range of therapeutic areas. It produces oral solid doses, injectables, and products with complex dosage forms.
äŒæ¥ã³ãŒãVTRS
äŒæ¥åViatris Inc
æé«çµå¶è²¬ä»»è
ãCEOãSmith (Scott A)
ãŠã§ããµã€ãhttps://www.viatris.com/en
æ ªäž»çµ±èšî
ãããã質å
Viatris IncïŒVTRSïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îViatris IncïŒVTRSïŒã®çŸåšã®æ ªäŸ¡ã¯17.64ã§ãã
Viatris Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îViatris Incã®ãã£ãã«ãŒã·ã³ãã«ã¯VTRSã§ãã
Viatris Incã®52é±é«å€ã¯ãããã§ããïŒ
îViatris Incã®52é±é«å€ã¯17.53ã§ãã
Viatris Incã®52é±å®å€ã¯ãããã§ããïŒ
îViatris Incã®52é±å®å€ã¯8.40ã§ãã
Viatris Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îViatris Incã®æäŸ¡ç·é¡ã¯20.30Bã§ãã
Viatris Inc (VTRS) ã®çŸåšã®è©äŸ¡ã¯ãè²·ããããããŒã«ãããã売ããã®ã©ãã§ããïŒ
îã¢ããªã¹ãã«ãããšãViatris IncïŒVTRSïŒã®ç·åè©äŸ¡ã¯è²·ãã§ãç®æšæ ªäŸ¡ã¯17.59ã§ãã
Viatris Inc (VTRS) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îViatris IncïŒVTRSïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-3.00ã§ãã